Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Operations (2016 - 2025)

Viking Therapeutics' Cash from Operations history spans 12 years, with the latest figure at 85290000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 173.53% year-over-year to 85290000.0; the TTM value through Dec 2025 reached 278685000.0, down 217.45%, while the annual FY2025 figure was 278685000.0, 217.45% down from the prior year.
  • Cash from Operations for Q4 2025 was 85290000.0 at Viking Therapeutics, up from 94003000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6134000.0 in Q1 2024 and bottomed at 94003000.0 in Q3 2025.
  • The 5-year median for Cash from Operations is 15569500.0 (2022), against an average of 26791700.0.
  • The largest annual shift saw Cash from Operations skyrocketed 75.11% in 2024 before it tumbled 753.13% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 12350000.0 in 2021, then rose by 11.53% to 10926000.0 in 2022, then tumbled by 61.45% to 17640000.0 in 2023, then crashed by 76.76% to 31181000.0 in 2024, then crashed by 173.53% to 85290000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Cash from Operations are 85290000.0 (Q4 2025), 94003000.0 (Q3 2025), and 47061000.0 (Q2 2025).